VCs won't go near traditional diagnostics. But some are starting to bet on biomarkers that expedite drug R&D and commercialization. Only one problem: they've yet to come up with the right business model
By Wendy Diller
"If I were to bet what health care will look like in five to ten years," a venture capitalist mused...
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The low-dose atropine eye drop slowed the progression of pediatric myopia by 30%.
EFPIA says reforms make the continent less attractive for innovative firms.
US green light will further expand sales of the prostate cancer blockbuster.
All eyes are on the upcoming readout of BPL-003 for treatment-resistant depression.
EFPIA says reforms make the continent less attractive for innovative firms.
Plus deals involving Roche/Vividion, Alto/Chase, Biogen/City Therapeutics, Sanofi/Nurix and Naya/Invo.
Private Company Edition: Six biopharma companies raised venture capital rounds totaling $100m or more in May, matching the number of mega-rounds in April and March. Among other recent financings, Syndeio launched with $90m and SpyGlass raised a $75m series D round.
